Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
Phase I Trial of Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
Sponsor: Northwell Health
Terminated
Low enrollment
Other terminated trials from Northwell Health
Other Carcinoma, Squamous Cell trials with similar outcome
A PHASE1 clinical study on Carcinoma, Squamous Cell and Carcinoma, Squamous Cell of Head and Neck, this trial is terminated or withdrawn. The trial is conducted by Northwell Health and has accumulated 12 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Jan 2021 — Dec 2021 [monthly]
Recruiting PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1
▶ Show 7 earlier versions
-
Sep 2019 — Oct 2020 [monthly]
Recruiting PHASE1
-
Jul 2019 — Sep 2019 [monthly]
Recruiting PHASE1
-
Jul 2018 — Jul 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1
-
Jul 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Jul 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Northwell Health
For direct contact, visit the study record on ClinicalTrials.gov .